Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoCo-Pro-RBD-1 and MIPSCo-mRNA-RBD-1 Booster in Healthy Adults
NCT05272605Phase 1Completed
- Sponsor
- University of Melbourne
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DoCo-Pro-RBD-1 + MF59 and SARS-CoV-2 beta variant RBD mRNA vaccine in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by University of Melbourne. Primary endpoints: Serious Adverse Events at Day 181, Serious Adverse Events Post Vaccination at Day 29 and 3 more. Started Apr 2022; status: completed.
02
Drugs
DoCo-Pro-RBD-1 + MF59SARS-CoV-2 beta variant RBD mRNA vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05272605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272605.